Markets experienced a range of pronounced swings on Monday as company-specific news and analyst actions reshaped performance across market-cap tiers. Technology and biotech headlines were particularly influential, with some mega-cap names advancing and several smaller companies seeing very large percentage changes.
Mega-Cap Movers ($200 billion USD or higher)
- Oracle Corp (ORCL) - Oracle adds document review, inspection tools to Aconex platform: +11.14%
- Intel Corp (INTC): +4.13%
- Microsoft Corp (MSFT) - OpenAI touts Amazon alliance in memo, says Microsoft has 'limited our ability' to reach clients - CNBC: +3.05%
- United Health Group (UNH): +2.26%
- IBM (IBM): +2.46%
- AbbVie Inc (ABBV): -1.91%
- Coca-Cola Co (KO): -1.98%
- Goldman Sachs Group (GS): -2.5%
Large-Cap Stock Movers ($10-$200 billion USD)
- Revolution Medicines Inc (RVMD) - Revolution Medicines reports positive phase 3 pancreatic cancer trial: +38.79%
- Avis Budget (CAR): +15.59%
- Credo Technology Holding (CRDO) - Jefferies initiates Credo Technology stock with buy rating on AI growth: +10.95%
- Astera Labs (ALAB): +9.11%
- Fair Isaac and Comp Inc (FICO): +9.35%
- Circle Internet Group Inc (CRCL): +9.35%
- CoreWeave (CRWV): +9.08%
- Cloudflare Inc (NET) - Cloudflare expands agent cloud infrastructure for AI developers: +9.06%
- Snowflake Inc (SNOW): +8.91%
- Yandex (NBIS) - Freedom Capital Markets downgrades Nebius stock rating on valuation concerns: +8.06%
Mid-Cap Stock Movers ($2-$10 billion USD)
- Aeglea Bio Therapeutics Inc (SYRE) - Spyre reports positive phase 2 data for ulcerative colitis drug: +26.25%
- Oaktree Acquisition Corp (HIMS): +10.24%
- Rubrik (RBRK): +9.93%
- Braze (BRZE): +9.07%
- Ringcentral Inc (RNG): +8.57%
- SailPoint Tech (SAIL): +8.44%
- Nutanix Inc (NTNX): +8.43%
- Robert Half Intl (RHI): +8.18%
- Tempus AI (TEM) - Jefferies initiates Tempus AI stock with underperform rating: +7.73%
- Varonis Systems (VRNS): +7.83%
Small-Cap Stock Movers ($300 million - $2 billion USD)
- Replimune Group Inc (REPL) - JPMorgan downgrades Replimune stock rating after second FDA rejection: -65.02%
- Aimei Health Tech (AFJK): -27.56%
- Omnilit Acquisition (OPTX): +22.35%
- MMTEC (MTC): +21.33%
- Allogene Therapeutics Inc (ALLO) - Allogene reports interim data from lymphoma trial: +15.26%
- Beta Bionics Inc (BBNX): +18.12%
- Sigma Lithium US (SGML): +17.27%
- Gloo Holdings Ltd (GLOO): +15.73%
- Zentalis Pharmaceuticals LLC (ZNTL): -15.28%
- SNXX (SNXX): +17.39%
Across the market-cap breakdowns, Monday's moves were driven by a mix of product announcements, analyst research notes, trial readouts, and regulatory and valuation concerns. The largest percentage swings were concentrated in smaller-cap biotechnology names, while technology and cloud-related companies showed broad strength among larger-cap issues.
Context and market implications
The day's activity underscored how discrete company developments - from new product capabilities to trial outcomes and analyst actions - can produce outsized changes in share prices. Tech and AI-related developments appeared frequently in the headlines for advancing stocks, while regulatory and analyst downgrades had notable negative impacts among certain biotechs and financial firms.